Insys Therapeutics (NASDAQ: INSY) reported Q3 EPS of ($0.21), $0.06 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $30.67 million versus the consensus estimate of $36.69 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.